January 15, 2020

Press release

Excellent result of FluoGuide’s FG001 guiding surgical removal of cancer is published

FluoGuide A/S’s (“FluoGuide”) compound FG001 lights up the cancer and its invasive growth and has demonstrated potential to vastly improve the... [Read more]

January 9, 2020

Press release

Safety study initiated with FG001

FluoGuide A/S (“FluoGuide”) hereby announces that the first in vivo dosing of FG001 will commence today. This is an important milestone... [Read more]

November 29, 2019

Press release

Interim Report Third Quarter 2019

FluoGuide A/S (“FluoGuide”) today announces its results for the period 01/July/2019 – 30/Sep/2019. The full report is available on the company’s... [Read more]

September 7, 2019

Press release

Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve... [Read more]

September 6, 2019

Press release

Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve... [Read more]

August 30, 2019

Press release

Interim Report Second Quarter 2019

FluoGuide today publishes its interim report for the period January – June 2019. The report is available here.   Andreas Kjær,... [Read more]

August 20, 2019

Press release

Strong preclinical data on FG001’s potential in guiding surgical removal of pancreatic cancer has been accepted for presentation on the World Molecular Imaging Congress 2019

FluoGuide A/S’s (“FluoGuide”) compound FG001 lights up the cancer and has demonstrated potential to vastly improve the radicality of surgery in... [Read more]